Grimes & Company, Inc. Adma Biologics, Inc. Transaction History
Grimes & Company, Inc.
- $3.66 Billion
- Q3 2024
A detailed history of Grimes & Company, Inc. transactions in Adma Biologics, Inc. stock. As of the latest transaction made, Grimes & Company, Inc. holds 23,285 shares of ADMA stock, worth $493,176. This represents 0.01% of its overall portfolio holdings.
Number of Shares
23,285
Previous 39,987
41.77%
Holding current value
$493,176
Previous $447,000
4.03%
% of portfolio
0.01%
Previous 0.01%
Shares
8 transactions
Others Institutions Holding ADMA
# of Institutions
319Shares Held
185MCall Options Held
917KPut Options Held
91.6K-
Black Rock Inc. New York, NY18.6MShares$395 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA18.1MShares$384 Million0.01% of portfolio
-
State Street Corp Boston, MA13MShares$275 Million0.01% of portfolio
-
Invesco Ltd. Atlanta, GA12.6MShares$267 Million0.05% of portfolio
-
Morgan Stanley New York, NY8.6MShares$182 Million0.01% of portfolio
About ADMA BIOLOGICS, INC.
- Ticker ADMA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 196,356,992
- Market Cap $4.16B
- Description
- ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primar...